Navigation Links
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Date:12/2/2008

riod, as compared to ibuprofen, in patients at risk for NSAID-induced ulcers. The primary objective of REDUCE-2 was to evaluate HZT-501 in reducing the proportion of patients who develop endoscopically diagnosed gastric and/or duodenal ulcers during the 24-week treatment period, as compared to ibuprofen, in patients at risk for NSAID-induced ulcers. The trials were conducted via a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA).

Patients, who had mild-to-moderate pain, including those with osteoarthritis, were randomly assigned, in approximately a 2:1 ratio, to receive HZT-501 (800 mg ibuprofen and 26.6 mg famotidine) or ibuprofen (800 mg) alone orally three times daily for a 24- week treatment period or until patients developed either an endoscopically diagnosed upper gastrointestinal ulcer and/or prohibitive toxicity. Patients received endoscopies at baseline and weeks 8, 16 and 24. 8025 Lamon Avenue, Suite 110, Skokie, IL 60077

In REDUCE-1, 24-week treatment with HZT-501 resulted in a statistically significant reduction in gastric ulcers versus treatment with ibuprofen alone. In REDUCE-2, 24-week treatment with HZT-501 resulted in a statistically significant reduction in gastric and/or duodenal ulcers versus treatment with ibuprofen alone.

Treatment with both HZT-501 and ibuprofen alone were well tolerated in the studies. The majority were mild to moderate in severity. There were no significant differences between the two treatment groups adverse event or serious adverse event profiles.

"NSAIDs can cause significant gastrointestinal damage, including ulcers of the stomach and duodenum," said Loren Laine, MD, professor of medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California. "These results indicate that HZT-501 can reduce the risk of ulcers, potentially improving the GI safety
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
2. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
3. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
4. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
5. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
6. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
9. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
10. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
11. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... SAN DIEGO , May 26, 2015 /PRNewswire/ ... in developing targeted therapeutic devices to address infectious ... A. Joyce , Chief Executive Officer, will present ... on Thursday, May 28th.  Details of Aethlon Medical,s ... Microcap Investor Conference Date: , Thursday, May 28, ...
(Date:5/26/2015)... , May 26, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York City. The public is welcome to ... the Array BioPharma website.Event: Jefferies 2015 Global Healthcare ... p.m. Eastern Time Webcast: www.arraybiopharma.com  About Array BioPharma ...
(Date:5/26/2015)... 26, 2015  LabStyle Innovations Corp. (DRIO), ... announced today that in partnership with ... Healthcare, it has launched  the comprehensive Dario™ ... advanced Telecare unit (MOMA). The Dario™ is ... enables remote treatment for diabetes aiming to ...
Breaking Medicine Technology:Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 2Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 3Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference 4LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 2LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 3LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 4
... Carrot Medical, a leading manufacturer of integrated medical imaging display ... the year, Carrot Medical achieved significant growth in sales and ... half of 2011 with record second quarter sales, Carrot surpassed ...  The company is now well positioned for the third straight ...
... comedienne and TV favourite Jo Brand has joined forces with ... brand new comedy film (54 seconds) to launch Macmillan Cancer ... Jo Brand running around South London, in what looks like ... with Joanna Scanlan and produces a pint of milk; it ...
Cached Medicine Technology:Carrot Medical Positioned for Third Straight Year of Triple Digit Growth 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 3
(Date:5/26/2015)... Carey Danis & Lowe provides ... . The suit pertains to AndroGel, a testosterone gel ... late April 2015, and a court document relating to ... in mid-May.¹ , Testosterone gel lawsuits are being consolidated ... of Illinois. The multidistrict litigation (MDL) is In Re: ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Degeneration of ... early marker of specific types of Alzheimer’s disease (AD), ... study published in the journal Radiology. , “Alzheimer’s ... Ph.D., co-author of the study conducted at the Neuroimaging ... “However, white matter damage has a central role in ...
(Date:5/26/2015)... MD (PRWEB) May 27, 2015 ... Order Contract (MATOC) by the United States Department of ... Center (PSC). The MATOC was awarded through ... Supply Schedule (FSS) for the PSC, which is a ... with four one year options, and is an enterprise–wide ...
(Date:5/26/2015)... The world of cosmetic plastic surgery ... to remain on the cutting edge of all new ... new additions to plastic surgery and his practice. There ... with emphasis on facelifts and mommy-makeovers all of which ... friendly and easy to navigate. The sites have a ...
(Date:5/26/2015)... May 26, 2015 Forex Income Boss ... in improving their results trading in the foreign exchange ... Russ Horn, utilizes 10 customer indicators to help traders ... , "As usual, Russ Horn's latest trading system is ... trading community," reports Tiffany Hendricks, senior product reviewer at ...
Breaking Medicine News(10 mins):Health News:Carey Danis & Lowe Comments on Recently Filed Testosterone Gel Lawsuit 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 3Health News:Securityhunter Has Been Awarded a Multiple Award Task Order Contract (MATOC) by the Department of Health and Human Services 2Health News:Miguel Delgado, M.D. Launches Two New Plastic Surgery Websites 2Health News:Miguel Delgado, M.D. Launches Two New Plastic Surgery Websites 3Health News:Forex Income Boss - Review Of Russ Horn's New FX Trading System Released 2
... -- an antibiotic being prescribed to people who may ... growth when taken by pregnant women. Instead, the Centers ... Cipro to pregnant women. The recommendation comes as health ... general population, possibly causing common bacteria to become resistant ...
... study, a trial of a new anti-cancer drug interacts ... a natural product, is being tested as an anti-cancer treatment. ... of the drug on the genes that are activated in ... affected by ceflatonin. These experiments have been done in human ...
... advertisements of prescription drugs, statements about drug benefits ... quantify the medications' expected benefit; instead, they make ... Medical School, Hanover, New Hampshire. // ... is that the medicine is going to prevent ...
... warn that gout can be incredibly painful, and if not ... belief, gout can strike at any time, and for no ... rich food and wine, and women can be affected too, ... affect middle-aged men and some people find an attack follows ...
... pregnant women at risk of the potentially fatal condition ... and E. ,The study, published in the Lancet, found ... pre-eclampsia. ,The condition involves the pregnant mother with ... of the unborn child through the placenta. ,Between ...
... who snore when they are pregnant may be at risk ... lives when they give birth. Around 10% of pregnant women ... can lead to injury or even death in the mother ... pressure by resting or with medication. But drugs may put ...
Cached Medicine News:Health News:Snoring could be a warning 2
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Lyphochek Benzo/TCA Control Set A is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and tricyclic antidepressant drugs....
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Medicine Products: